证券代码：688799 证券简称：华纳药厂 公告编号：2025-041 湖南华纳大药厂股份有限公司 第四届监事会第三次临时会议决议公告 公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会议召开情况 二、监事会会议审议情况 本次会议审议通过了如下议案： （一）审议通过《关于延长公司 2024 年度向特定对象发行 A 股股票股东大 会决议有效期的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 表决结果：3 票同意，0 票反对，0 票弃权。 本议案尚需提交股东大会审议。 （二）审议通过《关于提请股东大会延长授权董事会全权办理 2024 年度向 特定对象发行 A 股股票相关事宜的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 表决结果：3 票同意，0 票反对，0 票弃权。 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届监事会第三次临 时会议于 2025 年 4 月 30 日以现场结合通讯方式召开，本次会议的通知于 2 ...

证券代码：688799 证券简称：华纳药厂 公告编号：2025-040 湖南华纳大药厂股份有限公司 第四届董事会第四次临时会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 湖南华纳大药厂股份有限公司（以下简称"公司"）第四届董事会第四次临 时会议于 2025 年 4 月 30 日以现场结合通讯方式召开，本次会议的通知于 2025 年 4 月 29 日送达公司全体董事，本次会议经全体董事同意豁免会议通知时间要 求。会议由董事长黄本东先生主持，应出席董事 7 人，实际出席董事 7 人。会议 的召集、召开、表决程序符合相关法律、法规及《湖南华纳大药厂股份有限公司 章程》（以下简称"《公司章程》"）的相关规定，所作决议合法有效。 二、董事会会议审议情况 本次会议审议通过了如下议案： （一）审议通过《关于延长公司 2024 年度向特定对象发行 A 股股票股东大 会决议有效期的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的相 关公告。 本议案已经第四届董事会第二 ...

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

Policy Developments - The National Medical Products Administration (NMPA) released the "Quality Management Specifications for Online Sales of Medical Devices," effective from October 1, 2025, which emphasizes qualification review, information transparency, and risk prevention for online medical device sales [1] Drug and Device Approvals - Insilico Medicine's INS018_055 tablet is expected to receive breakthrough therapy designation for treating idiopathic pulmonary fibrosis [2] - Yuyuan Pharmaceutical's injectable Ganciclovir has passed the consistency evaluation for generic drugs, which will enhance the company's market share and competitiveness [3] - Warner Pharmaceuticals' Bismuth Potassium Citrate Granules have also passed the consistency evaluation for generic drugs, benefiting future market sales [4] - Changchun High-tech's subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of Fuxin Qibai monoclonal antibody injection, aimed at treating endometriosis [5] Financial Reports - Yunnan Baiyao reported a Q1 2025 net profit of 1.935 billion yuan, a 13.67% increase year-on-year, with total revenue of 10.841 billion yuan, up 0.62% [6] - WuXi AppTec's Q1 2025 net profit surged by 89.06% to 3.672 billion yuan, driven by revenue growth and operational efficiency improvements [7][8] - Kefu Medical's 2024 annual report showed a net profit increase of 22.6% to 312 million yuan, with revenue of 2.983 billion yuan, up 4.53% [9] - Hongbo Pharmaceutical's Q1 2025 net profit increased by 226.47% to 11.974 million yuan, with revenue of 16.9 million yuan, up 29.61% [10] Capital Market Activities - Jiangsu Hengrui Medicine has received approval from the China Securities Regulatory Commission for its Hong Kong IPO, planning to issue up to 815.1 million shares [11] - Merck announced its acquisition of SpringWorks for approximately $3.9 billion in equity value [12] - China Merchants Bio intends to increase its stake in Renfu Pharmaceutical by 0.5%-1% within six months, reflecting confidence in the company's future [13] Industry Developments - Xiangyu Medical expects to obtain registration certificates for seven robotic products by 2025, focusing on rehabilitation and other medical applications [14] - Soundon Medical has formed a strategic partnership with MED-EL's BHM to advance global bone conduction hearing solutions [16] - Hanyu Pharmaceutical signed a comprehensive cooperation agreement with Huawei Cloud to focus on "AI Smart Drugs" in drug development [17] Public Sentiment Alerts - Innovative Medical announced that shareholder Shanghai Guanghuan Technology reduced its stake by 3.41 million shares, representing 0.8191% of the total circulating shares [18]

Summary of Key Points Core Viewpoint - The financing balance of the Sci-Tech Innovation Board has decreased for three consecutive trading days, indicating a potential shift in investor sentiment and market dynamics [1][2]. Financing Balance - As of April 28, the total financing balance on the Sci-Tech Innovation Board is 149.40 billion yuan, down by 523.46 million yuan from the previous trading day [1]. - The highest financing balance is held by SMIC at 7.25 billion yuan, followed by Cambrian and Haiguang Information with 5.38 billion yuan and 3.34 billion yuan respectively [1]. - A total of 279 stocks saw an increase in financing balance, while 305 stocks experienced a decrease [1]. Margin Trading Balance - The total margin trading balance is 5.22 billion yuan, which is a decrease of 1.73 million yuan from the previous trading day [1]. - The highest margin trading balance is also held by SMIC at 26 million yuan, followed by Haiguang Information and Cambrian with 22 million yuan and 20 million yuan respectively [2]. - 103 stocks saw an increase in margin trading balance, while 152 stocks experienced a decrease [2]. Notable Changes in Financing and Margin Trading - Significant increases in financing balance were observed in Warner Pharmaceuticals (31.90%), Longxin Technology (14.02%), and Yubang Power (14.01%) [2]. - The largest decreases in financing balance were seen in Zhenhua Wind Power (-15.51%), Jushi Chemical (-15.30%), and Tianwei Electronics (-12.50%) [1]. - In margin trading, notable increases were recorded for Kesi Technology (406.67%), China Electric Research (160.27%), and Yaokang Bio (124.94%) [2]. - The largest decreases in margin trading were noted for Fangyuan Co. (-77.74%), Aerospace Huanyu (-51.43%), and Gai Lun Electronics (-47.06%) [2].

Group 1: Smartphone Market - Xiaomi has regained the top position in the Chinese smartphone market after ten years, with a shipment of 13.3 million units and a market share of 18.6%, representing a year-on-year growth of 39.9% [2] - Huawei shipped 11.2 million units with a market share of 15.7%, showing a year-on-year increase of 10% [2] - Apple experienced a decline, shipping 9.8 million units and a market share of 13.7%, down 10% year-on-year [2] Group 2: Corporate Developments - Apple is restructuring its teams, moving its robotics team to the hardware department, indicating dissatisfaction with its AI and machine learning leadership [3] - Cyberspace Group has submitted an application for listing on the Hong Kong Stock Exchange, with joint sponsors being CICC and China Galaxy International [4] - Warner Pharmaceuticals has received approval for its bismuth potassium citrate granules, which will enhance its market competitiveness [12] Group 3: Financial Performance - CICC reported a net profit of 2.042 billion yuan for Q1, a year-on-year increase of 64.85%, with revenues of 5.721 billion yuan, up 47.69% [9] - WuXi AppTec achieved a net profit of 3.672 billion yuan in Q1, marking a year-on-year growth of over 89% [10] - Shanghai Pharmaceuticals reported a net profit of 1.333 billion yuan in Q1, down 13.56% year-on-year [11] Group 4: Consumer Goods - Lao Feng Xiang reported a net profit of 613 million yuan in Q1, a decrease of 23.55% year-on-year, with revenues of 17.521 billion yuan, down 31.64% [13] - Three squirrels reported a net profit of 239 million yuan in Q1, a decline of 22.46% year-on-year, with revenues of 3.723 billion yuan, up 2.13% [16] Group 5: New Initiatives - China Petroleum & Chemical Corporation has commenced construction on a 30,000-ton carbon fiber project, expected to be completed by 2027, supporting the new materials industry [22][23] - ZTE is entering the companion robot market, planning to launch products focused on security monitoring and emotional companionship [6] Group 6: Market Trends - TikTok is implementing new regulations to combat malicious marketing accounts, introducing a health score mechanism for accounts [8] - The dining reservation volume for the upcoming holiday has surged, with Haidilao receiving over 25,000 reservations for the first day of the holiday [15]

证券代码：688799 证券简称：华纳药厂 公告编号：2025-038 2、剂型：颗粒剂 3、规格：120mg（按 Bi₂O₃计） 4、注册分类：化学药品 5、受理号：CYHB2350709 6、原药品批准文号：国药准字 H43020409 7、上市许可持有人：湖南华纳大药厂股份有限公司 表性胃炎以及伴有幽门螺杆菌感染时，其主要成分枸橼酸铋钾是一种组成不定的 含铋复合物，可在胃的酸性环境中形成弥散性的保护层覆盖于溃疡面上，阻止胃 酸、酶及食物对溃疡的侵袭，同时还可降低胃蛋白酶活性，增加粘蛋白分泌，促 进黏膜释放前列腺素，从而保护胃黏膜。另外，枸橼酸铋钾对幽门螺杆菌（HP） 具有杀灭作用，因而可促进胃炎的愈合。 湖南华纳大药厂股份有限公司 自愿披露关于药品通过仿制药质量和疗效一致性评 价的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的关于枸橼酸铋钾颗粒的《药品补充申请批准通知书》。现将 相关情况公告如下： 一、药品基本信息 1、药品名 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Views - The pharmaceutical sector is expected to experience positive growth factors in 2025, driven by innovation, international expansion, and an aging population [4][5] - The report highlights the significant unmet demand for new drugs in the epilepsy and depression markets, suggesting potential investment opportunities in companies like Hainan Haiyao and Warner Pharmaceuticals [3][4] Summary by Sections Epilepsy Market Potential - Approximately 9 million epilepsy patients in China, with about 30% unresponsive to current treatments, indicating a substantial market opportunity [10][11] - The anti-epileptic drug market in China is projected to exceed 10 billion yuan, with significant growth potential for innovative drugs targeting KCNQ channels [4][10][12] Depression Treatment Demand - Depression poses a major public health threat, with a global market for antidepressants expected to reach $17.6 billion by 2030 [39] - The report emphasizes the urgent need for rapid-acting and effective treatments for major depressive disorder with suicidal ideation (MDSI), highlighting the limitations of traditional antidepressants [41][43] Key Companies and Products - Warner Pharmaceuticals' ZG001, a modified version of ketamine, shows promise in treating depression without addiction risks, currently in clinical trials [47] - Johnson & Johnson's Spravato (esketamine) is the only approved treatment for MDSI, with projected sales reaching $3 billion by 2027 [44][45] Industry Trends - The report notes a successful transition from generic to innovative drug development in China, with companies like Heng Rui Medicine and Kelun Pharmaceutical leading the way [5] - The aging population is driving demand for treatments related to chronic diseases, further enhancing the growth prospects for the pharmaceutical sector [5]

证券代码：688799 证券简称：华纳药厂 公告编号：2025-037 湖南华纳大药厂股份有限公司 自愿披露关于获得药品注册证书的公告 6、受理号：CYHS2400290 7、药品批准文号：国药准字 H20253917 8、上市许可持有人：湖南华纳大药厂股份有限公司 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，湖南华纳大药厂股份有限公司（以下简称"公司"）收到国家药品监 督管理局核准签发的硫酸沙丁胺醇注射液《药品注册证书》，现将相关情况公告 如下： 一、药品相关信息 1、药品名称：硫酸沙丁胺醇注射液 2、剂 型：注射剂 3、规 格：1ml:0.5mg（按 C₁₃H₂₁NO₃计） 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 3 类 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范 要求方可生产销售。 二、药品的相关情况 硫酸沙丁胺醇注射液适用 ...